The use of diflunisal for transthyretin cardiac amyloidosis: a review
The use of diflunisal for transthyretin cardiac amyloidosis: a review
About this item
Full title
Author / Creator
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Transthyretin cardiac amyloidosis (ATTR-CM) is caused by the accumulation of misfolded transthyretin (TTR) protein in the myocardium. Diflunisal, an agent that stabilizes TTR, has been used as an off-label therapeutic for ATTR-CM. Given limited data surrounding the use of diflunisal, a systematic review of the literature is warranted. We searched t...
Alternative Titles
Full title
The use of diflunisal for transthyretin cardiac amyloidosis: a review
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3108444936
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3108444936
Other Identifiers
ISSN
1382-4147
E-ISSN
1573-7322
DOI
10.1007/s10741-021-10143-4
